ADRB2 and arthritic joint disease: Treatment of rats with adjuvant arthritis (AA) with the nonselective α-AR blocker phenoxybenzamine, the selective α1AR antagonist prazosin, the selective α2AR antagonist yohimbine, the nonselective β-AR blocker propranolol, the selective β1AR antagonist metoprolol, or the selective β2AR antagonists butoxamine and ICI 118551 (ICI) respectively, showed that only the two β2AR antagonists effectively reduced arthritis manifestations [10, 11].